Crenel Lateral Interbody Fusion Combined With Lateral Plate Fixation for LSS Combined With Lumbar Instability

NCT ID: NCT06058143

Last Updated: 2023-09-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

98 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-30

Study Completion Date

2026-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

At present, interbody fusion is the mainstream treatment for patients with lumbar spinal stenosis (LSS) and lumbar instability. However, the choice of interbody fusion for LSS patients with lumbar instability remains controversial. Recently, we developed crenel lateral interbody fusion combined with lateral plate fixation(CLIF - LP) for patients with LSS and lumbar instability. This surgical method has many advantages and showed good results for patients with LSS and lumbar instability. Therefore, we propose the following hypothesis: The clinical and imaging efficacy of CLIF-LP in the treatment of LSS patients with lumbar instability is not inferior to that of traditional transforaminal lumber interbody fusion (TLIF).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

At present, interbody fusion is the mainstream treatment for patients with lumbar spinal stenosis (LSS) and lumbar instability. However, the choice of interbody fusion for LSS patients with lumbar instability remains controversial. Recently, we developed crenel lateral interbody fusion combined with lateral plate fixation(CLIF - LP) for patients with LSS and lumbar instability. This surgical method has the advantages of direct view operation, "safe" psoas major approach, application of modified retractor, and lateral plate reinforcement, which not only significantly improves the postoperative lumbar function and nerve function of patients with LSS and lumbar instability, but also significantly reduces related complications, accelerates rehabilitation, and reduces the medical cost of patients.

Therefore, we propose the following hypothesis: The clinical and imaging efficacy of CLIF-LP in the treatment of LSS patients with lumbar instability is not inferior to that of traditional transforaminal lumber interbody fusion (TLIF).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lumbar Spinal Stenosis Lumbar Instability

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Patients who received CLIF-LP treatment

Group Type EXPERIMENTAL

CLIF-LP

Intervention Type PROCEDURE

CLIF-LP surgery method was applied

Group 2

Patients who received TLIF treatment

Group Type ACTIVE_COMPARATOR

TLIF

Intervention Type PROCEDURE

TLIF surgery method was applied

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CLIF-LP

CLIF-LP surgery method was applied

Intervention Type PROCEDURE

TLIF

TLIF surgery method was applied

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 50-80 years old
2. Patients diagnosed with clinical symptoms of lumbar spinal stenosis, neurogenic intermittent claudication, the patient's walking ability is highly limited, and the quality of life is severely reduced
3. Imaging diagnosis of 1-2 LSS patients, consistent with clinical symptoms
4. Lumbar spine instability can be considered if one of the following three criteria is met: ① mechanical back pain with severe (VAS \> 7) (pain aggravates with weight bearing). Radiographs of lumbar hyperextension and flexion show a slip of at least 3mm between the two vertebrae, or a rotation Angle of 11°. ③ Degenerative slip
5. Formal conservative treatment is ineffective for more than 3 months
6. No history of lumbar surgery
7. American College of Physicians ASA Grade I or II
8. Subjects voluntarily sign informed consent as subjects

Exclusion Criteria

1. In patients with significant symptoms of lumbar radiculopathy, the pain from postural changes cannot be relieved
2. Bone stenosis, including developmental lumbar spinal stenosis
3. Free nucleus pulposus tissue into the spinal canal or cause spinal canal compression of the small joint cyst
4. Patients with hypertrophy of the yellow ligament or small joint cyst as the main pressure
5. Intervertebral space or posterior facet joints have fused
6. Infectious, traumatic and neoplastic diseases of the lumbar spine
7. Patients who are unable to undergo MRI
8. Some medical conditions, such as metabolic bone disease, autoimmune disease, poliomyelitis sequelae, osteoporosis, history of poor bone healing, and long-term oral steroids, were determined by the investigators to be unsuitable for inclusion in the study
9. Patients with evidence of neurological disorders (such as peripheral neuropathy), neuromuscular disorders (such as multiple sclerosis, Parkinson's disease, etc.), or systemic diseases (such as inflammatory arthritis) that affect bodily function
10. The patient has participated in other clinical trials in the past 3 months
11. Patients with poor adherence, judged by the researchers to be unable to complete the trial according to the study plan, such as schizophrenia and dementia, did not provide consent to volunteer to participate in the clinical study
Minimum Eligible Age

50 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ning Zhang, PhD

Role: STUDY_DIRECTOR

Second Affiliated Hospital, School of Medicine, Zhejiang University

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Zhan Wang, PhD

Role: CONTACT

-8618758586092

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Mars515

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Modified Mini-Open TLIF vs Traditional Open TLIF
NCT07279051 NOT_YET_RECRUITING NA